Description

Simple

A medication used to treat attention deficit hyperactivity disorder (ADHD) and daytime sleepiness.

Clinical

A sympathomimetic agent used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.

Overview

Dextroamphetamine is the dextrorotary enantiomer of amphetamine[5]. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[6,Label].

Pharmacology

Indication

Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD)[Label].

Pharmacodynamic

Dextroamphetamine is a noncatecholamine, sympathomimetic amine that acts as a CNS stimulant[Label]. Dextroamphetamine raises systolic and diastolic blood pressure, acts as a weak bronchodilator, and also acts as a respiratory stimulant[Label]. The general mechanism of action of dextroamphetamine has... Read more

Mechanism of action

The exact mechanism of amphetamines as a class is not known. Dextroamphetamine acts by preventing reuptake, increasing release, and stimulating reverse-transport of dopamine in synaptic clefts in the striatum[ Read more

Absorption

Bioavailability data of dextroamphetamine is not readily available, however there is no difference in bioavailability when taken with or without a meal[Label].

Protein binding

Information currently not available.

Volume of distribution

195L[ Read more

Clearance

17L/h[ Read more

Half life

11.75 hours[Label]. In a study of post-stroke patients the half life was 16.0 hours in females and 12.4 hours in males[ Read more

Route of elimination

A third of the drug is eliminated renally[5].

Toxicity

Dexrtoamphetamine has been shown to be teratogenic and embryotoxic in mice at 41 times the maximum human dose[Label]. These effects were not seen in rat or rabbit studies, and the effects on human pregnancy have not been studied[Label]. The risk and benefit of use during pregnancy should be weighed... Read more

Adverse Effects

Contraindications

  • Route:
    • Oral
  • Dose Form:
    • Tablet
    • Tablet, extended release
  • Hypersensitivity:
    • true
  • Sex Group: all
  • Regions: US
  • Regions: US
  • Patient Conditions:
      • Name: Advanced arteriosclerosis
      • Drugbank Id: DBCOND0107486
  • Regions: US
  • Patient Conditions:
      • Name: Symptomatic cardiovascular disease
      • Drugbank Id: DBCOND0107487
      • Modification Of:
        • Base:
          • Name: Cardiovascular Disease
          • Drugbank Id: DBCOND0028376
        • Severity:
          • Includes:
            • symptomatic
  • Regions: US
  • Patient Conditions:
      • Name: Moderate to Severe Hypertension
      • Drugbank Id: DBCOND0042937
  • Regions: US
  • Patient Conditions:
      • Name: Hyperthyroidism
      • Drugbank Id: DBCOND0009048
  • Regions: US
  • Patient Conditions:
      • Name: Glaucoma
      • Drugbank Id: DBCOND0010013
  • Regions: US
  • Patient Conditions:
      • Name: Agitated states
      • Drugbank Id: DBCOND0108374
  • Regions: US
  • Patient Conditions:
      • Name: History of drug abuse
      • Drugbank Id: DBCOND0107489
  • Regions: US
  • With Categories Coadmin:
      • Name: Monoamine Oxidase Inhibitors
      • Drugbank Id: DBCAT001004
      • Mesh Id: D008996

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Dextroamphetamine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
The metabolism of Dextroamphetamine can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid
The risk or severity of hypertension can be increased when Dextroamphetamine is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
1-benzylimidazole
The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Dextroamphetamine.
2,5-Dimethoxy-4-ethylamphetamine
The risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Dextroamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of serotonin syndrome can be increased when Dextroamphetamine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthine
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine.
3,5-diiodothyropropionic acid
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 3,5-diiodothyropropionic acid.
3,5-Diiodotyrosine
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 3,5-Diiodotyrosine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of serotonin syndrome can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Dextroamphetamine.
4-Methoxyamphetamine
The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Dextroamphetamine.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of serotonin syndrome can be increased when Dextroamphetamine is combined with 5-methoxy-N,N-dimethyltryptamine.
6-O-benzylguanine
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 6-O-benzylguanine.
7-Deazaguanine
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 7-Deazaguanine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Dextroamphetamine.
7,9-Dimethylguanine
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 7,9-Dimethylguanine.
8-azaguanine
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 8-azaguanine.
8-chlorotheophylline
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 8-chlorotheophylline.
9-Deazaguanine
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 9-Deazaguanine.
9-Methylguanine
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 9-Methylguanine.
Abaloparatide
The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Abaloparatide.
6 References
  1. 1 . de la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, Pichini S: Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. Clin Pharmacokinet. 2004;43(3):157-85. doi: 10.2165/00003088-200443030-00002.PubMed: 14871155
  2. 2 . Saunders C, Galli A: Insights in how amphetamine ROCKs (Rho-associated containing kinase) membrane protein trafficking. Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):15538-9. doi: 10.1073/pnas.1520960112. Epub 2015 Nov 25.PubMed: 26607447
  3. 3 . Dolder PC, Strajhar P, Vizeli P, Hammann F, Odermatt A, Liechti ME: Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects. Front Pharmacol. 2017 Sep 7;8:617. doi: 10.3389/fphar.2017.00617. eCollection 2017.PubMed: 28936175
  4. 4 . Calipari ES, Ferris MJ: Amphetamine mechanisms and actions at the dopamine terminal revisited. J Neurosci. 2013 May 22;33(21):8923-5. doi: 10.1523/JNEUROSCI.1033-13.2013.PubMed: 23699503
  5. 5 . Martinsson L, Yang X, Beck O, Wahlgren NG, Eksborg S: Pharmacokinetics of dexamphetamine in acute stroke. Clin Neuropharmacol. 2003 Sep-Oct;26(5):270-6.PubMed: 14520168
  6. 6 . FDA Drug Approval Package for Dextroamphetamine Link